Biospecifics Tech Cp (BSTC) Stock Price, Quote, News and Overview
NASDAQ:BSTC - Nasdaq -
BSTC Quote, Performance and Key Statistics
88.53
+0.13 (+0.15%)
The current stock price of BSTC is 88.53 null. In the past month the price increased by 0.4%. In the past year, price increased by 59.92%.
About BSTC
Company Profile
BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (``FDA``) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals.
Company Info
Biospecifics Tech Cp
2 Righter Parkway Suite 200
Wilmington DE 19803
CEO: J. Kevin Buchi
Phone: 302-842-8450
Biospecifics Tech Cp / BSTC FAQ
What is the stock price of Biospecifics Tech Cp today?
The current stock price of BSTC is 88.53 null. The price increased by 0.15% in the last trading session.
What is the ticker symbol for Biospecifics Tech Cp stock?
The exchange symbol of Biospecifics Tech Cp is BSTC and it is listed on the Nasdaq exchange.
On which exchange is BSTC stock listed?
BSTC stock is listed on the Nasdaq exchange.
What is Biospecifics Tech Cp worth?
Biospecifics Tech Cp (BSTC) has a market capitalization of 650.25M null. This makes BSTC a Small Cap stock.
What are the support and resistance levels for Biospecifics Tech Cp (BSTC) stock?
Biospecifics Tech Cp (BSTC) has a support level at 88.44 and a resistance level at 88.54. Check the full technical report for a detailed analysis of BSTC support and resistance levels.
Should I buy Biospecifics Tech Cp (BSTC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BSTC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BSTC, evaluating the profitability, health, valuation and growth aspects
- Biospecifics Tech Cp (BSTC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Biospecifics Tech Cp (BSTC) Sales and EPS estimates to see what analysts future expectations are.
- Biospecifics Tech Cp (BSTC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Biospecifics Tech Cp (BSTC) Insider and Institutional Ownership to learn about the owners and their transactions.
- Biospecifics Tech Cp (BSTC) Stock Chart to make your own analysis
- Biospecifics Tech Cp (BSTC) Latest news and press-releases to stay up to date.
Does Biospecifics Tech Cp (BSTC) stock pay dividends?
BSTC does not pay a dividend.
What is the Price/Earnings (PE) ratio of Biospecifics Tech Cp (BSTC)?
The PE ratio for Biospecifics Tech Cp (BSTC) is 33.92. This is based on the reported non-GAAP earnings per share of 2.61 and the current share price of 88.53 null. Check the full fundamental report for a full analysis of the valuation metrics for BSTC.
BSTC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to BSTC. When comparing the yearly performance of all stocks, BSTC is one of the better performing stocks in the market, outperforming 90.02% of all stocks.
BSTC Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BSTC. BSTC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
BSTC Financial Highlights
Over the last trailing twelve months BSTC reported a non-GAAP Earnings per Share(EPS) of 2.61. The EPS decreased by -17.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 47.43% | ||
| ROA | 12.64% | ||
| ROE | 12.83% | ||
| Debt/Equity | 0 |
BSTC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 60% to BSTC. The Buy consensus is the average rating of analysts ratings from 1 analysts.